Biora Therapeutics (BIOR) Competitors $0.15 +0.01 (+6.50%) As of 06/13/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock BIOR vs. ADTX, JAGX, ONCO, SCNI, QLGN, PTN, AWH, ALZN, PCSA, and APVOShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Aditxt (ADTX), Jaguar Animal Health (JAGX), Onconetix (ONCO), Scinai Immunotherapeutics (SCNI), Qualigen Therapeutics (QLGN), Palatin Technologies (PTN), Aspira Women's Health (AWH), Alzamend Neuro (ALZN), Heatwurx (PCSA), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Its Competitors Aditxt Jaguar Animal Health Onconetix Scinai Immunotherapeutics Qualigen Therapeutics Palatin Technologies Aspira Women's Health Alzamend Neuro Heatwurx Aptevo Therapeutics Biora Therapeutics (NASDAQ:BIOR) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, BIOR or ADTX? Aditxt has lower revenue, but higher earnings than Biora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora Therapeutics$892K0.74-$124.11M-$13.04-0.01Aditxt$130K19.99-$34.45MN/AN/A Which has more risk & volatility, BIOR or ADTX? Biora Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Do insiders and institutionals believe in BIOR or ADTX? 43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BIOR or ADTX more profitable? Biora Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -46,082.47%. Biora Therapeutics' return on equity of 0.00% beat Aditxt's return on equity.Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -332.47% Aditxt -46,082.47%-389.10%-84.71% Do analysts recommend BIOR or ADTX? Biora Therapeutics currently has a consensus target price of $23.00, suggesting a potential upside of 15,664.22%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Biora Therapeutics is more favorable than Aditxt.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aditxt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer BIOR or ADTX? In the previous week, Aditxt had 1 more articles in the media than Biora Therapeutics. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for Biora Therapeutics. Aditxt's average media sentiment score of 0.76 beat Biora Therapeutics' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media. Company Overall Sentiment Biora Therapeutics Neutral Aditxt Positive SummaryBiora Therapeutics beats Aditxt on 8 of the 14 factors compared between the two stocks. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$660K$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio-0.011.1327.5020.21Price / Sales0.74226.97421.02118.64Price / CashN/A23.4436.8958.07Price / Book0.006.298.045.67Net Income-$124.11M-$27.73M$3.18B$249.13M7 Day PerformanceN/A1.21%2.82%3.30%1 Month Performance-2.73%9.47%3.70%5.20%1 Year Performance-97.67%7.77%35.41%21.38% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics2.122 of 5 stars$0.15+6.5%$23.00+15,664.2%-97.7%$660K$892K-0.01120Gap UpADTXAditxtN/A$1.22-5.1%N/A-100.0%$2.58M$130K0.0060News CoverageJAGXJaguar Animal Health1.9096 of 5 stars$2.50-0.8%$60.00+2,300.0%-97.1%$2.55M$11.69M0.0050ONCOOnconetix0.3161 of 5 stars$4.73-0.8%N/A-99.1%$2.51M$2.52M0.0012Positive NewsSCNIScinai ImmunotherapeuticsN/A$2.49+9.0%N/A-28.8%$2.49M$660K-0.2620Positive NewsGap UpHigh Trading VolumeQLGNQualigen TherapeuticsN/A$3.35-1.8%N/A-62.9%$2.48M$4.98M0.0050Gap UpPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.959 of 5 stars$0.08-12.5%$5.50+6,607.3%-91.3%$2.44M$9.18M-0.07110High Trading VolumeALZNAlzamend Neuro2.6351 of 5 stars$2.91flat$180.00+6,085.6%-91.6%$2.33MN/A0.004Positive NewsGap UpPCSAHeatwurx3.6646 of 5 stars$0.20-4.9%$2.00+925.6%-89.3%$2.32MN/A-0.0620News CoverageAnalyst RevisionGap UpAPVOAptevo Therapeutics2.141 of 5 stars$2.99-2.0%$219,040.00+7,325,652.5%-100.0%$2.27M$3.11M0.0050 Related Companies and Tools Related Companies Aditxt Competitors Jaguar Animal Health Competitors Onconetix Competitors Scinai Immunotherapeutics Competitors Qualigen Therapeutics Competitors Palatin Technologies Competitors Aspira Women's Health Competitors Alzamend Neuro Competitors Heatwurx Competitors Aptevo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOR Stock Alerts